| 邱录贵 | 中国医学科学院血液病医院 | Insight of Pathogenesis and Current Treatment in CLL |
| Ken C. Anderson | DFCI, Harvard Medical School | Multiple Myeloma: State of Art and Prospect |
| Nikhil C. Munshi | DFCI, Harvard Medical School | Genomic, Clonal Evolution and MRD in MM |
| Yu-Tzu Tai | DFCI, Harvard Medical School | Immuno-microenvironment and Immunotherapy in myeloma |
| Qing Yi | Cleveland Clinic | Targeting Microenvironment for Myeloma Therapy |
| Shaji Kumar | Mayo Clinic | Risk Adopted Treatment Strategy in Myeloma |
| Meletios Dimopoulos | National and Kapodistrian University of Athens | Monoclonal Antibody based immunotherapy for myeloma |
| Antony Palumbo | Takeda International | Advances of PIs in the treatment of Myeloma |
| Fenghuang Zhan | University of IOWA | Advances on Biology Study in Myeloma |
| Gang An | 中国医学科学院血液病医院 | Translational Study on Myeloma in IHCAMS |
| Julie M. Vose | University of Nebraska Medical Center | PTCL: Current Situation, Challenging and Prospect |
| John Chan | City of Hope Medical Center | Advances in Pathogenesis and Diagnosis of T-cell lymphoma |
| Ken He Young | MDACC | B Cell Lymphoma : Pathogenensis and Targeting therapy |
| Huiqiang Huang | 中山大学肿瘤医院 | Treatment in NK/T Cell Lymphoma: Current and Prospect |